Gastrointestinal Bleeding Risk in Ischemic Heart Disease on Antiplatelet Therapy

This clinical study focuses on patients with ischemic heart disease, a condition where blood flow to the heart is restricted due to narrowed or blocked arteries. The study aims to understand the frequency and risk of gastrointestinal bleeding, which is bleeding within the digestive system, in patients who are treated with either single or dual antiplatelet therapy. Antiplatelet medications like aspirin and clopidogrel are used to prevent blood clots and reduce heart attack risk, but they can also increase the chance of bleeding in the digestive tract. The study seeks to find ways to minimize these bleeding risks while maintaining the effectiveness of heart disease treatment. Participants in this study are observed to compare the rates of gastrointestinal bleeding between those on single antiplatelet therapy and those on dual therapy. The study is observational, meaning it does not involve any experimental treatment; instead, it monitors patients' health outcomes under their current medication regimens. Researchers measure the occurrence of bleeding events, looking at whether the use of one or two antiplatelet drugs affects the likelihood of bleeding complications. The ultimate goal is to identify safer treatment strategies for managing heart disease without increasing the risk of gastrointestinal issues.